News
June 18, 2019

Regenstrief scientist explains how class of drugs may be related to dementia

Regenstrief research scientist Noll Campbell, PharmD, M.S., spoke about a common class of drugs and how it affects the brain on an Indianapolis radio show.

Dr. Campbell was a guest on Caregiver Crossing, which airs every Saturday on 93.1 WIBC. Dr. Campbell addressed the topic of anticholinergics and their potential link to Alzheimer’s and dementia. Anticholinergics are a common class of drug that includes some allergy medications, sleeping pills and many more common medicines.

Dr. Campbell recently received a $3.3 million grant from the National Institute on Aging to conduct the first clinical trial designed to determine if stopping these medications results in sustained improvements in cognition.

Listen to his discussion with the Caregiver Crossing hosts and his advice for people who are taking these medications.

Segment 1

Segment 2

Click here for more information on Caregiver Crossing.

  • Noll Campbell, PharmD, MS

Related News

Dr. Chris Callahan

Effect of modernized collaborative care for depression on depressive symptoms and cardiovascular disease risk biomarkers: eIMPACT randomized controlled trial

Published in the journal Brain, Behavior and Immunity. Here is a link to the article. Regenstrief Institute authors: Christopher

National health IT leader Micky Tripathi to visit Regenstrief Institute

Micky Tripathi, PhD, MPP, the national coordinator for health information technology at the U.S. Department of Health and Human

Dr. Babar Khan on All IN

Mobile Critical Care Recovery Program for Survivors of Acute Respiratory Failure: A Randomized Clinical Trial

Published in JAMA Network Open. Here is a link to the article. Regenstrief Institute authors: Babar Khan, M.D., M.S.,

Expanding health equity by including nursing home residents in clinical trials

INDIANAPOLIS – Clinical trials are constantly being designed and study participants enrolled to determine if medical treatments and therapies